公开(公告)号：US20230041584A1

公开(公告)日：2023-02-09

申请号：US17836984

申请日：2022-06-09

申请人： ATAI Life Sciences AG

发明人： Robert B. PERNI ,  Glenn SHORT ,  Srinivas G. RAO

IPC分类号： C07D209/16 ,  C07D209/14 ,  C07F9/572 ,  C07D401/06 ,  C07D403/06 ,  C07D209/08 ,  C07D209/12

摘要： Provided herein are compounds of Formula (I), or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R8, R9, X, Y, Z, W, and m are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.

公开(公告)号：US20230031944A1

公开(公告)日：2023-02-02

申请号：US17935256

申请日：2022-09-26

申请人： Beckley Psytech Limited

发明人： Cosmo FEILDING-MELLEN ,  Timothy MASON

IPC分类号： C07D209/16 ,  A61P25/24

摘要： An intranasal composition comprising a dosage amount of 50-150 mg/ml 5-methoxy-N,N-dimethyltryptamine (5MeODMT) in a liquid medium, wherein the 5MeODMT is formulated as the chloride salt of 5MeODMT (5MeODMT hydrochloride) and wherein the 5MeODMT hydrochloride is crystalline and characterised by one or more of: peaks in an XRPD diffractogram; an endothermic event in a DSC thermograph; an onset of decomposition in a TGA thermograph; and a DVS isotherm profile.

公开(公告)号：US20220363635A1

公开(公告)日：2022-11-17

申请号：US17743776

申请日：2022-05-13

申请人： CAAMTECH, INC.

发明人： Andrew R. CHADEAYNE

IPC分类号： C07D209/16 ,  A61K31/4045 ,  A61K36/185

摘要： Crystalline forms of 4-acetoxy-N,N-dimethyltryptamine (psilacetin), compositions containing that crystalline form, and their methods of use are disclosed. The crystalline forms of 4-acetoxy-N,N-dimethyltryptamine (psilacetin) according to the disclosure include crystalline 4-acetoxy-N,N-dimethyltryptammonium hydrofumarate, the fumarate salt of psilacetin, and/or crystalline bis(4-acetoxy-N,N-dimethyltryptammonium) fumarate, and pharmaceutical compositions containing a crystalline form of psilacetin.

公开(公告)号：US11478449B1

公开(公告)日：2022-10-25

申请号：US17866477

申请日：2022-07-16

申请人： Psilera Inc.

发明人： Christopher G. Witowski ,  Jacqueline L. Salm

IPC分类号： A61K31/4045 ,  A61K9/06 ,  A61K9/00 ,  A61K9/20 ,  A61K9/70 ,  A61K31/405 ,  A61K31/48 ,  A61K31/55 ,  A61K31/675 ,  C07D209/16

摘要： Pharmaceutical formulations of novel indole compounds and psilocybin analogs are manufactured, provided in novel oral, transdermal, and nasal pharmaceutical compositions for use to treat neurological, mood or abuse diseases and disorders.

公开(公告)号：US11358934B2

公开(公告)日：2022-06-14

申请号：US16827075

申请日：2020-03-23

申请人： CAAMTECH LLC

发明人： Andrew R. Chadeayne

IPC分类号： A61K31/4045 ,  C07D209/16 ,  A61K36/185

摘要： Crystalline forms of 4-acetoxy-N,N-dimethyltryptamine (psilacetin), compositions containing that crystalline form, and their methods of use are disclosed. The crystalline forms of 4-acetoxy-N,N-dimethyltryptamine (psilacetin) according to the disclosure include crystalline 4-acetoxy-N,N-dimethyltryptammonium hydrofumarate, the fumarate salt of psilacetin, and/or crystalline bis(4-acetoxy-N,N-dimethyltryptammonium) fumarate, and pharmaceutical compositions containing a crystalline form of psilacetin.

公开(公告)号：US20220119346A1

公开(公告)日：2022-04-21

申请号：US17564707

申请日：2021-12-29

申请人： CYBIN IRL LIMITED

发明人： Alex NIVOROZHKIN ,  Michael PALFREYMAN

IPC分类号： C07D209/16

摘要： The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor.

公开(公告)号：US20210403425A1

公开(公告)日：2021-12-30

申请号：US17364047

申请日：2021-06-30

申请人： Field Trip Psychedelics Inc.

发明人： Nathan Bryson

IPC分类号： C07D209/16 ,  C07D209/08 ,  A61K9/00 ,  A61K9/08

摘要： The present invention provides a tryptamine prodrug compound. A compound represented by the formula (I) where each symbol is as described in the specification, or a salt or zwitterion thereof, is converted to an active which has 5HT2A receptor agonist activity, and is useful as an agent for the treatment of depression.

公开(公告)号：US20210363104A1

公开(公告)日：2021-11-25

申请号：US17394038

申请日：2021-08-04

申请人： CYBIN IRL LIMITED

发明人： Alex NIVOROZHKIN ,  Michael PALFREYMAN

IPC分类号： C07D209/16

摘要： The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor.

公开(公告)号：US20210292278A1

公开(公告)日：2021-09-23

申请号：US16827075

申请日：2020-03-23

申请人： CAAMTECH LLC

发明人： Andrew R. CHADEAYNE

IPC分类号： C07D209/16 ,  A61K36/185 ,  A61K31/4045

摘要： Crystalline forms of 4-acetoxy-N,N-dimethyltryptamine (psilacetin), compositions containing that crystalline form, and their methods of use are disclosed. The crystalline forms of 4-acetoxy-N,N-dimethyltryptamine (psilacetin) according to the disclosure include crystalline 4-acetoxy-N,N-dimethyltryptammonium hydrofumarate, the fumarate salt of psilacetin, and/or crystalline bis(4-acetoxy-N,N-dimethyltryptammonium) fumarate, and pharmaceutical compositions containing a crystalline form of psilacetin.

公开(公告)号：US10555919B2

公开(公告)日：2020-02-11

申请号：US15525375

申请日：2015-11-12

申请人： The Brigham and Women's Hopsital, Inc.

发明人： Mauricio Farez ,  Francisco J. Quintana ,  Jorge Correale

IPC分类号： A61K31/343 ,  G01N33/74 ,  A61K31/165 ,  A61K31/4045 ,  A61K45/06 ,  C07D209/16

摘要： Methods for treating, or reducing risk of developing, seasonal worsening of multiple sclerosis (MS) in a subject who has MS, comprising administering a melatonin agonist to a subject.